UK Medical Cannabis, CBD Company Cannaray Announces Series A Funding
Medical marijuana and CBD company Cannaray announced the closing Monday of a 7.8-million pounds sterling ($9.64 million) Series A funding round.
Cannaray is “perfectly poised” to take advantage of the current market and has the infrastructure to become one to Europe’s leading medical cannabis and CBD brands, the company said.
Cannaray said it expects the global medical cannabis market set to grow to over 60 billion pounds by 2026.
Click here for more information about the upcoming Benzinga Cannabis Capital Conference Oct. 22-23 in Chicago.
Brexit-Proof With Ireland Setup
Cannaray’s strategy has been made "Brexit-proof" with the setup of a subsidiary in the Republic of Ireland, and the company said it is progressing with plans to establish distribution and manufacturing capabilities within the U.K.
Cannaray also has an alliance with Newey Limited, the largest horticultural company in the U.K. with 4 million square feet of greenhouse space.
Related Links:
Innovative Industrial Properties Provides Additional M To Ascend Wellness Subsidiary
Cannabis M&A: Therapix Biosciences, Destiny Biosciences Plan Stock-For-Stock Deal
See more from Benzinga
© 2019 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
